Massachusetts-based SpectraWAVE has gained considerable momentum in recent years, planting its flag in some of cardiology’s biggest trends. The company was co-founded by cardiologists and has already secured multiple FDA clearances. Massachusetts-based SpectraWAVE has gained considerable momentum in recent years, planting its flag in some of cardiology’s biggest trends. The company was co-founded by cardiologists and has already secured multiple FDA clearances. | | |
|
Milestone Pharmaceuticals will be selling etripamil under the brand name Cardamyst. It is expected to hit the U.S. market in early 2026. Milestone Pharmaceuticals will be selling etripamil under the brand name Cardamyst. It is expected to hit the U.S. market in early 2026. | | |
|
The new device uses an advanced algorithm to regulate aspiration and conserve blood. Ajit Rao, MD, a vascular surgeon with The Mount Sinai Hospital, performed the historic procedure. The new device uses an advanced algorithm to regulate aspiration and conserve blood. Ajit Rao, MD, a vascular surgeon with The Mount Sinai Hospital, performed the historic procedure. | | |
|
Three out of four TTEs are being ordered by clinicians who are not cardiologists. Could this be having a negative impact on patient care? Three out of four TTEs are being ordered by clinicians who are not cardiologists. Could this be having a negative impact on patient care? | | |
|
|
ASCs have their limitations, but they are also associated with several benefits for cardiologists and patients alike. ASCs have their limitations, but they are also associated with several benefits for cardiologists and patients alike. | | |
|
These most recent recalls focus on a series of maintenance issues. In 2024, the FDA advised customers to transition away from the two devices and find alternative treatment options. These most recent recalls focus on a series of maintenance issues. In 2024, the FDA advised customers to transition away from the two devices and find alternative treatment options. | | |
|
According to Heartflow, its AI offering saves health systems nearly $1,400 per patient thanks to reductions in unnecessary cardiovascular testing. According to Heartflow, its AI offering saves health systems nearly $1,400 per patient thanks to reductions in unnecessary cardiovascular testing. | | |
|
San Diego-based Vektor Medical first secured FDA clearance for the AI-powered technology back in 2021. This updated announcement covers the latest version, which includes atrial flutter mapping and several other new features. San Diego-based Vektor Medical first secured FDA clearance for the AI-powered technology back in 2021. This updated announcement covers the latest version, which includes atrial flutter mapping and several other new features. | | |
|
|
A growing number of private insurers are now covering these advanced technologies. Roosha Parikh, MD, told Cardiovascular Business that the hard work of SCCT and other groups has helped make this happen. A growing number of private insurers are now covering these advanced technologies. Roosha Parikh, MD, told Cardiovascular Business that the hard work of SCCT and other groups has helped make this happen. | | |
|
The recall was put in place after a hydrophilic coating was discovered on the inside of the devices. According to the FDA, patients treated with the catheters could face a number of significant risks. The recall was put in place after a hydrophilic coating was discovered on the inside of the devices. According to the FDA, patients treated with the catheters could face a number of significant risks. | | |
|
Approximately 3 million FreeStyle Libre 3 and FreeStyle Libre 3 Plus sensors need to be replaced due to a risk of incorrect glucose readings. Abbott has received reports of 736 severe adverse events and seven deaths that may be related to this issue. Approximately 3 million FreeStyle Libre 3 and FreeStyle Libre 3 Plus sensors need to be replaced due to a risk of incorrect glucose readings. Abbott has received reports of 736 severe adverse events and seven deaths that may be related to this issue. | | |
|
|
DECT systems allow for a contrast dose reduction of up to 25% during computed tomography pulmonary angiography exams. DECT systems allow for a contrast dose reduction of up to 25% during computed tomography pulmonary angiography exams. | | |
|
Yale New Haven failed to notify parents about the use of the cow-based formula, which they expressly asked staff not to use. A judge found that the hospital failed to stock a human alternative, known to be safer for premature newborns. Yale New Haven failed to notify parents about the use of the cow-based formula, which they expressly asked staff not to use. A judge found that the hospital failed to stock a human alternative, known to be safer for premature newborns. | | |
|
